Literature DB >> 22617308

Hepsin in the diagnosis of prostate cancer.

G Pace1, R Pomante, C Vicentini.   

Abstract

AIM: In the current study we verified whether the expression of hepsin in prostate cancer (PCa) of samples obtained from radical retropubic prostatectomies (RRP) was significantly different from the adjacent normal prostatic tissue. METHODS. We evaluate the expression of hepsin by using immunohistochemistry in PCa tissue in respect to the adjacent normal tissue, of 18 patients who underwent RRP.
RESULTS: Hepsin positive immunoreactivity was estimated on the staining intensity as negative (0), weakly positive (1+), moderately positive (2+), and strongly positive (3+). Hepsin immunoreactivity was detected in 100.0% PCa: 94.4% of cases showed a moderate/strong intensity, 5.6% a weak intensity. The adjacent benign prostatic tissue demonstrated a 83.3% of weak intensity, 11.1% had no reactivity and 5.6% were moderately intense. PCa demonstrated a significant higher (P<0.05) hepsin intensity (2.67) than the adjacent benign tissue (0.94).
CONCLUSION: Hepsin should be regarded as a novel potential immunohistochemical marker for the histopathological diagnosis of PCa.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617308

Source DB:  PubMed          Journal:  Minerva Urol Nefrol        ISSN: 0393-2249            Impact factor:   3.720


  5 in total

Review 1.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

Review 2.  ZBTB46, SPDEF, and ETV6: Novel Potential Biomarkers and Therapeutic Targets in Castration-Resistant Prostate Cancer.

Authors:  AbdulFattah Salah Fararjeh; Yen-Nien Liu
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

3.  Hepsin Promotes Epithelial-Mesenchymal Transition and Cell Invasion Through the miR-222/PPP2R2A/AKT Axis in Prostate Cancer.

Authors:  Ruiqian Li; Jun Li; Hong Yang; Yu Bai; Chen Hu; Hongyi Wu; Haiyang Jiang; Qilin Wang
Journal:  Onco Targets Ther       Date:  2020-11-24       Impact factor: 4.147

Review 4.  Clinical Significance of Hepsin and Underlying Signaling Pathways in Prostate Cancer.

Authors:  Lucy Lu; Adam Cole; Dan Huang; Qiang Wang; Zhongming Guo; Wancai Yang; Jim Lu
Journal:  Biomolecules       Date:  2022-01-25

Review 5.  Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

Authors:  Tamara Sequeiros; Marta García; Melania Montes; Mireia Oliván; Marina Rigau; Eva Colás; Inés de Torres; Juan Morote; Jaume Reventós; Andreas Doll
Journal:  Biomed Res Int       Date:  2013-11-25       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.